公开(公告)号：US20210147944A1

公开(公告)日：2021-05-20

申请号：US17046454

申请日：2019-04-10

Applicant: UNITY HEALTH TORONTO ,  UNIVERSITY HEALTH NETWORK

Inventor： George M. Yousef ,  Neil Eric Fleshner

IPC: C12Q1/6886 ,  G16B40/00 ,  G16B25/10

Abstract: The present disclosure provides methods for monitoring prostate cancer by determining or measuring exosomal miRNA levels in a biological sample to provide a biological sample exosomal miRNA profile comprising exosomal miRNA levels and determining or measuring the level of similarity of said biological sample exosomal miRNA profile to one or more control profiles. The present disclosure also provides kits for monitoring prostate cancer progression and methods for selecting a treatment for prostate cancer.

公开(公告)号：US20210062153A1

公开(公告)日：2021-03-04

申请号：US16900970

申请日：2020-06-14

Applicant: University Health Network

Inventor： Gordon Keller ,  Alec Drake Witty ,  Steven James Kattman

IPC: C12N5/077 ,  C12Q1/6881 ,  G01N33/50

Abstract: Methods and products for obtaining cardiovascular lineage cells from hPSCs. The method comprises one or more of the following steps: (a) contacting BMP component primed hPSCs with a cardiovascular mesoderm programming cocktail and culturing the contacted hPSCs for a period of time to generate a KDR+ and PDGFRalpha+ cardiovascular mesoderm cell population; (b) contacting the cardiovascular mesoderm cell population with a cardiovascular progenitor specification cocktail and culturing the contacted cardiovascular mesoderm cell population for a period of time to generate a NKX2-5+ or WT1+ cardiovascular progenitor cell population; and (c) contacting the cardiovascular progenitor cell population with a maturation cocktail and culturing the contacted cardiovascular progenitor population for a period of time to produce a cardiovascular population optionally cardiomyocyte lineage cells expressing cardiac troponin T (cTnT) and/or SIRPA and/or epicardial lineage cells expressing WT1.

公开(公告)号：US10919886B2

公开(公告)日：2021-02-16

申请号：US16675609

申请日：2019-11-06

Applicant: University Health Network

Inventor： Peter Brent Sampson ,  Miklos Feher ,  Heinz W. Pauls

IPC: C07D413/14

Abstract: A fumarate salt and a maleate salt of compound (I) represented by the following structural formula, as well as their corresponding pharmaceutical compositions, are disclosed. Particular single crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are also disclosed. The present invention also provides methods of treating a subject with a cancer.

公开(公告)号：US20200367818A1

公开(公告)日：2020-11-26

申请号：US16966293

申请日：2019-02-01

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： Ralph DaCOSTA ,  Christopher GIBSON ,  Kathryn OTTOLINO-PERRY ,  Nayana Thalanki ANANTHA ,  Susan Jane DONE ,  Wey-Liang LEONG ,  Alexandra M. EASSON

IPC: A61B5/00 ,  A61B90/30 ,  A61B90/00 ,  A61K41/00 ,  A61K49/00

Abstract: A method of assessing surgical margins is disclosed. The method includes, subsequent to administration of a compound configured to induce emissions of between about 600 nm and about 660 nm in cancerous tissue cells, positioning a distal end of a handheld, white light and fluorescence-based imaging device adjacent to a surgical margin. The method also includes, with the handheld device, substantially simultaneously exciting and detecting autofluorescence emissions of tissue cells and fluorescence emissions of the induced wavelength in tissue cells of the surgical margin. And, based on a presence or an amount of fluorescence emissions of the induced wavelength detected in the tissue cells of the surgical margin, determining whether the surgical margin is substantially free of at least one of precancerous cells, cancerous cells, and satellite lesions. The compound may be a non-activated, non-targeted compound such as ALA.

公开(公告)号：US10816552B2

公开(公告)日：2020-10-27

申请号：US16245328

申请日：2019-01-11

Applicant: The Governing Council of the University of Toronto ,  University Health Network

Inventor： Mark Nitz ,  Landon J. Edgar ,  Bradly G. Wouters ,  David Hedley ,  Lisa M. Willis ,  Matthew A. Lumba ,  Hanuel Park ,  Ravi N. Vellanki

IPC: G01N33/58 ,  C07D421/06 ,  C07D345/00 ,  C07H15/04 ,  G01N33/569

Abstract: A compound of formula (I): as described herein and methods and uses thereof as for mass tagging a biosensor or biologically active material.

公开(公告)号：US20200272864A1

公开(公告)日：2020-08-27

申请号：US16761577

申请日：2018-11-06

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： Kevin FAUST ,  Zoya VOLYNSKAYA ,  Ugljesa DJURIC ,  Phedias DIAMANDIS

IPC: G06K9/62 ,  G06T7/00 ,  G06N3/08 ,  G06N3/04

Abstract: Embodiments described herein provide a platform, device and process for digital pathology that enable multi-level annotation and visualization of histopathologic slides using a modular arrangement of deep convolutional neural networks (CNNs). The CNNs can be trained using pathology images (e.g., in some cases increasing the base of data by breaking larger fields of view into smaller ones) to learn features consistent with certain pathologies. The platform can use the CNNs to visually annotate pathology slides at an interface tool of a display device. The platform can automate the process of selection, as well as provide an opportunity for the pathologist to see a depiction of predicted results. The platform can use the CNNs to identify regions of interest on pathology slides. The interface tool can enable a predicted region of interest (ROI) type to be visually presented on a surface map showing the basis of the prediction. If the ROI primarily lands in part of the hyperdimensional space not occupied by any training set, then the interface tool is capable of marking it as an ROI of unknown type.

公开(公告)号：US20200270259A1

公开(公告)日：2020-08-27

申请号：US16806392

申请日：2020-03-02

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： Sze-Wan Li ,  Heinz W. Pauls ,  Peter Brent Sampson

IPC: C07D487/04 ,  A61P35/00 ,  C30B29/58 ,  C30B7/14 ,  C30B7/02 ,  A61K31/519

Abstract: The present invention relates to a novel co-crystal of the compound of formula (I): wherein the co-former molecule is bisphosphate hemihydrate, to processes for the preparation of the co-crystal, to pharmaceutical compositions containing the co-crystal, to the use of such a co-crystal in the manufacture of a medicament for use in the treatment of cancer and to methods of treating such diseases in the human or animal body by administering a therapeutically effective amount of such a co-crystal.

公开(公告)号：US20200230413A1

公开(公告)日：2020-07-23

申请号：US16253390

申请日：2019-01-22

Applicant: General Electric Company ,  University Health Network

Inventor： Radhika Madhavan ,  Gavin Elias ,  Alexandre Boutet ,  Suresh Joel

IPC: A61N1/36 ,  A61N1/05 ,  A61B5/00 ,  G16H10/60

Abstract: A system and method for identifying a patient-specific neurosurgery target location is provided. The system receives brain imaging data for a patient that includes tracts and networks in the patient brain, accesses a quantitative connectome atlas comprising population-based, disease-specific structural and functional connectivity maps comprising a pattern of tracts and networks associated with an optimal target area (OTA) identified from a population of patients, and defines the patient-specific neurosurgery target location based on a comparison between a pattern of the tracts and networks from the brain imaging data for the patient and the pattern of tracts and networks associated with the OTA identified from the population of patients in the quantitative connectome atlas. The quantitative connectome atlas comprises a disease-specific, population-based quantitative connectome atlas that identifies an optimal target location for treatment associated with a maximal clinical improvement for each disease in the population of patients.

公开(公告)号：US10711246B2

公开(公告)日：2020-07-14

申请号：US14915992

申请日：2014-09-12

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： Gordon Keller ,  Alec Drake Witty ,  Steven James Kattman

IPC: C12N5/077 ,  C12Q1/6881 ,  G01N33/50

Abstract: Provided are methods and products for obtaining cardiovascular lineage cells from hPSCs. The method for obtaining a cardiomyocyte lineage or an epicardial lineage cell population from human pluripotent stem cells (hPSCs) comprises one or more of the following steps: (a) contacting BMP component primed hPSCs with a cardiovascular mesoderm programming cocktail suitable for inducing the hPSCs to differentiate to a cardiovascular mesoderm cell population under conditions suitable for the programming cocktail to penetrate the hPSCs and culturing the contacted hPSCs for a period of time to generate a KDR+ and PDGFRalpha+ cardiovascular mesoderm cell population; (b) contacting the cardiovascular mesoderm cell population with a cardiovascular progenitor specification cocktail suitable to specify a NKX2-5+ or WT1+ cardiovascular progenitor cell population under conditions suitable for the specification cocktail to penetrate the cardiovascular mesoderm cell population and culturing the contacted cardiovascular mesoderm cell population for a period of time to generate a NKX2-5+ or WT1+ cardiovascular progenitor cell population; and (d) contacting the cardiovascular progenitor cell population with a maturation cocktail under conditions suitable for the maturation cocktail to penetrate the cardiovascular progenitor cell population and culturing the contacted cardiovascular progenitor population for a period of time to produce a cardiovascular population optionally cardiomyocyte lineage cells expressing cardiac troponin T (cTnT) and/or SIRPA and/or epicardial lineage cells expressing WT1.

公开(公告)号：US20200181582A1

公开(公告)日：2020-06-11

申请号：US16619883

申请日：2018-06-06

Applicant: THE MEDICAL COLLEGE OF WISCONSIN, INC ,  UNIVERSITY HEALTH NETWORK ,  WASHINGTON UNIVERSITY IN ST. LOUIS

Inventor： Jeffrey A. Medin ,  John F. Dipersio ,  Murtaza S. Nagree

IPC: C12N9/04 ,  C12N7/00 ,  C12N15/86 ,  C12N9/40 ,  C12N9/24 ,  C12N9/80 ,  A61K35/28 ,  C12N5/0789 ,  A61P43/00 ,  A61K9/00

Abstract: The present invention is related to a dual promoter lentiviral vector and methods of use for the treatment of diseases and disorders, specifically lysosomal storage disorders.